GlassScriptPhysician profile
Kristy A Weiss
NPI 1093318297
$1,871.16
in general payments reported to CMS, 2019-2025
14 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.38 · 2023: $142 · 2024: $574 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $529.23 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $276.01 | 2024-2025 | |
| Lilly USA, LLC | $249.65 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $208.16 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Horizon Therapeutics Plc | $124.84 | 2023 | Krystexxa |
| Abbvie INC. | $123.75 | 2023-2025 | |
| Amgen INC. | $94.31 | 2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $86.95 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $79.03 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $28.65 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Integra Lifesciences Corporation | $19.03 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Phathom Pharmaceuticals, INC. | $18.14 | 2025 | Voquezna |
| Lundbeck LLC | $18.03 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristy Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.